PMOS will be fully implemented in the 2028 International Guideline update

PMOS 将在 2028 年国际指南更新中全面实施。

image credit- freepik

图片来源：freepik

Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), following a 14-year global effort, led by Monash University in Australia, to improve diagnosis and care.

在澳大利亚莫纳什大学领导的一项为期14年的全球努力之后，多囊卵巢综合症 (PCOS) 已被更名为多内分泌代谢卵巢综合症 (PMOS)，以改进诊断和护理。

The condition, affecting more than 170 million women worldwide, or more than one in eight, was misunderstood to be “all about ovarian cysts”.

这种影响全球超过 1.7 亿女性（超过八分之一）的疾病被误解为“全是关于卵巢囊肿”。

PMOS is characterised by fluctuations in hormones, with impacts on weight, metabolic and mental health, skin, and the reproductive system.

PMOS 的特点是激素波动，影响体重、代谢和心理健康、皮肤以及生殖系统。

Professor Helena Teede, Director, Monash Centre for Health Research & Implementation and endocrinologist, Monash Health, Melbourne, Australia, led the name change process after decades of research into the condition and seeing patient impacts first hand.

澳大利亚墨尔本蒙纳士健康中心内分泌学家、蒙纳士健康研究与实施中心主任海伦娜·蒂德教授领导了这一名称变更过程，她在对该疾病进行了数十年研究并亲眼目睹患者所受影响后推动了这一改变。

The name change took 14 years of global collaboration between experts and those with lived experience across six continents. Teede said it was the largest initiative to change the name of a medical condition.

名称更改历时 14 年，六大洲的专家和有亲身经历的人士开展了全球合作。蒂德表示，这是改变医疗状况名称的最大举措。

Transition to the new name will occur over three years, supported by a multi-pronged strategy with a view to greater awareness, enhanced diagnosis, improved care quality and patient satisfaction, and optimised outcomes across the broad features of the condition.

向新名称的过渡将在三年内发生，这一过程将受到多管齐下战略的支持，旨在提高意识、加强诊断、改善护理质量和患者满意度，并优化该疾病广泛特征下的结果。

This period will be supported by a major international education and awareness campaign, reaching healthcare professionals, governments, and researchers around the world. PMOS will be fully implemented in the 2028 International Guideline update.

这一时期将通过一项大型国际教育和宣传活动获得支持，覆盖全球的医疗保健专业人员、政府和研究人员。PMOS 将在 2028 年国际指南更新中得到全面实施。

Divya Balaji Kamerkar, Co-founder and CEO of Pinky Promise, India said, 'PCOS was always a misnomer. Most women don't have cysts. Many don't have irregular periods. And yet the entire diagnostic framework was built around a name that described the wrong thing. Renaming it to PMOS, Polyendocrine Metabolic Ovarian Syndrome, finally centres the conversation where it belongs: on metabolism, hormones, and whole body health.

印度Pinky Promise联合创始人兼首席执行官Divya Balaji Kamerkar表示：“PCOS一直都是个误称。大多数女性并没有囊肿，许多女性也没有月经不调。然而整个诊断框架却是围绕一个描述错误的名称建立的。将其更名为PMOS（多内分泌代谢卵巢综合症），终于将讨论重点放在了它应有的位置：代谢、激素和全身健康。”

At Pinky Promise, we have been building for exactly this reality. This is a win for every woman who was dismissed, misdiagnosed, or left to figure it out alone. But a name change is the beginning, not the destination.'.

在Pinky Promise，我们一直在为这一现实而努力。这是对每一位被忽视、误诊或独自解决问题的女性的胜利。但名称的改变只是一个开始，而非终点。